Literature DB >> 20552284

Reduction of [(18)F]fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma.

Tomohiko Yamane1, Masahiro Kikuchi, Shogo Shinohara, Michio Senda.   

Abstract

PURPOSE: The purpose of this study was to investigate the changes of tumor hypoxia as a result of neoadjuvant chemotherapy (NAC) by measuring the changes of [(18)F]fluoromisonidazole ([(18)F]FMISO) positron emission tomography (PET) uptake, as well as to look into the ability of [(18)F]FMISO PET to predict the NAC result. PROCEDURES: A total of 13 patients with locally advanced head and neck squamous cell carcinoma underwent [(18)F]FMISO PET scans before and after NAC. For analysis of PET index, maximum standardized uptake value, tumor-to-muscle ratio, and hypoxic volume (HV) were measured.
RESULTS: All PET indexes of [(18)F]FMISO significantly decreased after NAC. Although HV in primary tumor and a few indexes before NAC in responder was lower than that in nonresponder, none of the indexes were statistically significant.
CONCLUSIONS: Pretreatment [(18)F]FMISO could not predict NAC outcome in this study. However, [(18)F]FMISO uptake significantly decreased after NAC, and [(18)F]FMISO PET seemed to be a useful noninvasive tool for detecting hypoxia reduction after NAC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20552284     DOI: 10.1007/s11307-010-0365-2

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  19 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Phase I study of S-1 and nedaplatin for patients with recurrence of head and neck cancer.

Authors:  Takeshi Kodaira; Nobukazu Fuwa; Hiroyuki Tachibana; Satoshi Hidano
Journal:  Anticancer Res       Date:  2006 May-Jun       Impact factor: 2.480

3.  Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02.

Authors:  Danny Rischin; Rodney J Hicks; Richard Fisher; David Binns; June Corry; Sandro Porceddu; Lester J Peters
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

4.  Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue.

Authors:  K Kubota; M Tada; S Yamada; K Hori; S Saito; R Iwata; K Sato; H Fukuda; T Ido
Journal:  Eur J Nucl Med       Date:  1999-07

5.  Fully automated synthesis of [18F]fluoromisonidazole using a conventional [18F]FDG module.

Authors:  Seung Jun Oh; Dae Yoon Chi; Christoph Mosdzianowski; Jung Young Kim; Hee Seop Gil; Se Hun Kang; Jin Sook Ryu; Dae Hyuk Moon
Journal:  Nucl Med Biol       Date:  2005-11       Impact factor: 2.408

6.  Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.

Authors:  Susanne-Martina Eschmann; Frank Paulsen; Matthias Reimold; Helmut Dittmann; Stefan Welz; Gerald Reischl; Hans-Juergen Machulla; Roland Bares
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

7.  Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma.

Authors:  Kyubo Kim; Hong-Gyun Wu; Hak Jae Kim; Myung-Whun Sung; Kwang Hyun Kim; Se-Hoon Lee; Dae Seog Heo; Hee Jung Kim; Charn Il Park
Journal:  Head Neck       Date:  2009-09       Impact factor: 3.147

8.  The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography.

Authors:  Zhixiong Lin; James Mechalakos; Sadek Nehmeh; Heiko Schoder; Nancy Lee; John Humm; C Clifton Ling
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-03-15       Impact factor: 7.038

9.  Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study.

Authors:  A Paccagnella; M G Ghi; L Loreggian; A Buffoli; H Koussis; C A Mione; A Bonetti; F Campostrini; G Gardani; A Ardizzoia; D Dondi; M Guaraldi; R Cavallo; L Tomio; A Gava
Journal:  Ann Oncol       Date:  2009-12-23       Impact factor: 32.976

10.  pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia?

Authors:  Bernd Gagel; Marc Piroth; Michael Pinkawa; Patrick Reinartz; Michael Zimny; Hans J Kaiser; Sven Stanzel; Branka Asadpour; Cengiz Demirel; Kurt Hamacher; Heinz H Coenen; Thomas Scholbach; Payam Maneschi; Ercole DiMartino; Michael J Eble
Journal:  BMC Cancer       Date:  2007-06-28       Impact factor: 4.430

View more
  8 in total

Review 1.  Molecular imaging of tumor hypoxia with positron emission tomography.

Authors:  Olivia J Kelada; David J Carlson
Journal:  Radiat Res       Date:  2014-03-27       Impact factor: 2.841

2.  Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma.

Authors:  Jun Sato; Yoshimasa Kitagawa; Yutaka Yamazaki; Hironobu Hata; Takuya Asaka; Masaaki Miyakoshi; Shozo Okamoto; Tohru Shiga; Masanobu Shindoh; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-28       Impact factor: 9.236

Review 3.  Role of (18)F-FDG PET-CT in head and neck squamous cell carcinoma.

Authors:  P Castaldi; L Leccisotti; F Bussu; F Miccichè; V Rufini
Journal:  Acta Otorhinolaryngol Ital       Date:  2013-02       Impact factor: 2.124

Review 4.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 5.  Imaging tumour hypoxia with positron emission tomography.

Authors:  I N Fleming; R Manavaki; P J Blower; C West; K J Williams; A L Harris; J Domarkas; S Lord; C Baldry; F J Gilbert
Journal:  Br J Cancer       Date:  2014-12-16       Impact factor: 7.640

Review 6.  Molecular mechanisms of hypoxia in cancer.

Authors:  Amarnath Challapalli; Laurence Carroll; Eric O Aboagye
Journal:  Clin Transl Imaging       Date:  2017-05-11

7.  YC-1 sensitizes the antitumor effects of boron neutron capture therapy in hypoxic tumor cells.

Authors:  Takaomi Harada; Katsumi Hirose; Yuki Wada; Mariko Sato; Koji Ichise; Masahiko Aoki; Takahiro Kato; Ken Takeda; Yoshihiro Takai
Journal:  J Radiat Res       Date:  2020-07-06       Impact factor: 2.724

8.  A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy.

Authors:  Izumi Tachibana; Yasumasa Nishimura; Toru Shibata; Shuichi Kanamori; Kiyoshi Nakamatsu; Ryuta Koike; Tatsuyuki Nishikawa; Kazuki Ishikawa; Masaya Tamura; Makoto Hosono
Journal:  J Radiat Res       Date:  2013-04-14       Impact factor: 2.724

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.